Literature DB >> 6994313

Comparison of propranolol and inderal L.A. in patients with angina.

M E Scott, K Balnave.   

Abstract

TWELVE patients with moderately severe angina pectoris completed a double blind cross-over comparison of conventional propranolol (40 mg q.i.d.) and Inderal L.A. (160 mg once daily) with regard to therapeutic effectiveness, blood levels, compliance and patient acceptability.Exercise tolerance was assessed using standardised treadmill testing at 1, 2, 4, 8, 12 and 24 hours after the morning dose. The double placebo technique was used.Patient compliance was excellent for both regimes and no serious side effects were reported. No significant differences in exercise tolerance or blood levels were observed between the two treatments at any time.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994313      PMCID: PMC2385754     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


  5 in total

1.  Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors:  C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal:  Circulation       Date:  1975-08       Impact factor: 29.690

2.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

Review 3.  Stress testing methodology.

Authors:  L T Sheffield; D Roitman
Journal:  Prog Cardiovasc Dis       Date:  1976 Jul-Aug       Impact factor: 8.194

4.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

5.  Efficacy of beta adrenergic blockade in coronary heart disease: propranolol in angina pectoris.

Authors:  R R Miller; H G Olson; C M Pratt; E Z Amsterdam; D T Mason
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.